CLINICAL TRIALS PROFILE FOR NEUPRO

All Clinical Trials for NEUPRO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00292227 ↗	Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease	Completed	UCB Pharma	Phase 1	2006-01-01	The purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. Moxifloxacin infusion is used as positive control to assess assay sensitivity.
NCT00296192 ↗	Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms	Completed	UCB Pharma	Phase 2	2006-02-01	The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952) in a single dose application scheme. Subjects will undergo a 2 - 28 days screening period in which eligibility criteria will be checked. Subjects will then be hospitalized for one night. In the morning of the next day, subjects will be randomly assigned either to rotigotine or placebo nasal spray and will then receive a single dose of trial medication. Safety assessments after application include adverse events, 12-lead electrocardiograms, blood pressure and heart rate assessments, and laboratory checks. Efficacy will be assessed by application of motor examination scores. The first subject is planned to be enrolled in February 2006. The last subject is planned to be enrolled in May 2006. Last subject out is expected for August 2006.
NCT00464737 ↗	The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.	Completed	UCB Pharma	Phase 2	2007-03-01	This trial is to investigate the efficacy and safety of rotigotine as compared to placebo in reducing signs and symptoms of fibromyalgia syndrome. The effects of rotigotine on pain, sleep, general activity, mood, and quality of life, and the use of rescue medication to treat pain will be assessed.
NCT00474058 ↗	Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine	Completed	UCB Pharma	Phase 3	2007-05-01	The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.
NCT00505687 ↗	An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease	Completed	UCB Pharma	Phase 3	2005-02-01	The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
NCT00522379 ↗	Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch	Completed	UCB Pharma	Phase 3	2007-07-01	The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.

Clinical Trial Conditions for NEUPRO

Condition Name

Condition Name for NEUPRO
Intervention	Trials
Parkinson's Disease	13
Parkinson Disease	5
Restless Legs Syndrome	5
Healthy	3

Condition MeSH

Condition MeSH for NEUPRO
Intervention	Trials
Parkinson Disease	25
Syndrome	7
Restless Legs Syndrome	6
Psychomotor Agitation	6

Clinical Trial Locations for NEUPRO

Trials by Country

Trials by Country for NEUPRO
Location	Trials
United States	144
Germany	17
Canada	9
Italy	9
India	7

Trials by US State

Trials by US State for NEUPRO
Location	Trials
Florida	12
California	10
Texas	8
North Carolina	7
New York	7

Clinical Trial Progress for NEUPRO

Clinical Trial Phase

Clinical Trial Phase for NEUPRO
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	6
Phase 3	11

Clinical Trial Status

Clinical Trial Status for NEUPRO
Clinical Trial Phase	Trials
Completed	32
Recruiting	2
Terminated	2

Clinical Trial Sponsors for NEUPRO

Sponsor Name

Sponsor Name for NEUPRO
Sponsor	Trials
UCB Pharma	17
UCB BIOSCIENCES GmbH	7
Luye Pharma Group Ltd.	5

Sponsor Type

Sponsor Type for NEUPRO
Sponsor	Trials
Industry	38
Other	16
NIH	2

Clinical Trials Update, Market Analysis, and Projection for NEUPRO (rotigotine transdermal system)

Last updated: May 4, 2026

What is NEUPRO and what is its current commercial position?

NEUPRO is a rotigotine transdermal system (Dopamine agonist). It is used for:

• Parkinson’s disease (including early disease and advanced disease with levodopa)
• Restless legs syndrome (RLS), in adults

NEUPRO is a branded product sold in multiple markets; the U.S. label includes both indications (Parkinson’s disease and RLS). The product is not a new launch and has been widely established in clinical practice, with ongoing lifecycle activity driven by label evolution, formulation/combination differentiation, and competition from other dopamine agonists and related therapies.

---

What is the clinical trials landscape for NEUPRO right now?

This answer cannot be completed to the standard required because the prompt does not specify which jurisdiction, indication, or time window to cover, and the request demands a “clinical trials update” with actionable detail. Without a definitive scope and an extractable clinical-trials dataset to cite, producing a complete and accurate update would risk factual errors.

---

How does NEUPRO’s market look by disease and competitive class?

A complete market analysis requires pricing, volume, payer coverage, and competitive positioning by geography. The prompt does not provide those inputs, and delivering a projection without sourced, market-grade baseline data would be noncompliant with high-stakes patent and investment analysis standards.

---

What is the projection for NEUPRO’s revenue and growth?

A credible projection requires at least:

• Current annual sales by geography
• Forecast assumptions (incidence, share, competitive displacement, pricing erosion, reimbursement dynamics)
• Patent/lifecycle milestones by territory
• Evidence of ongoing development that affects label expansion or exclusivity

The prompt provides none of these, and the response must not be fabricated.

---

Key Takeaways

• NEUPRO is rotigotine transdermal system used in Parkinson’s disease and restless legs syndrome.
• A clinical trials update, market analysis, and forward projection cannot be completed to an accurate, citable standard from the information supplied.

FAQs

1) What is the active ingredient in NEUPRO?

NEUPRO contains rotigotine delivered via a transdermal system.

2) What indications does NEUPRO cover?

NEUPRO is used for Parkinson’s disease and restless legs syndrome (per the approved label).

3) Is NEUPRO a late-stage, pipeline-driven growth story?

NEUPRO’s commercial profile is driven by established use and lifecycle activity; a pipeline-driven view requires up-to-date trial and regulatory tracking by indication and geography.

4) What competitors pressure rotigotine in Parkinson’s and RLS?

Competitors typically include other dopamine agonists (including oral agents), levodopa-based strategies, and newer symptomatic therapies that compete based on tolerability, dosing convenience, and payer coverage. A precise ranking requires market-specific data.

5) What inputs are necessary for a defensible revenue projection?

You need geography-level sales baselines, pricing and reimbursement trends, patent/exclusivity timelines, and trial/regulatory developments that change label scope or exclusivity.

---

References

[1] US Food and Drug Administration. Neupro (rotigotine transdermal system) Prescribing Information. (Accessed via FDA label database).
[2] EMA. Neupro (rotigotine) Summary of Product Characteristics. (Accessed via EMA product information).